Compare · BDX vs SENS
BDX vs SENS
Side-by-side comparison of Becton Dickinson and Company (BDX) and Senseonics Holdings Inc. (SENS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and SENS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $41.33B, about 38.8x SENS ($1.07B).
- Over the past year, BDX is down 13.0% and SENS is down 32.7% - BDX leads by 19.7 points.
- SENS has been more active in the news (23 items in the past 4 weeks vs 10 for BDX).
- BDX has more recent analyst coverage (25 ratings vs 7 for SENS).
- Company
- Becton Dickinson and Company
- Senseonics Holdings Inc.
- Price
- $150.14-0.71%
- $7.13+6.97%
- Market cap
- $41.33B
- $1.07B
- 1M return
- -2.01%
- +32.62%
- 1Y return
- -12.95%
- -32.69%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- AMEX
- IPO
- News (4w)
- 10
- 23
- Recent ratings
- 25
- 7
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Senseonics Holdings Inc.
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to 90 and 180 days. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.
Latest BDX
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
- EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)
- New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Peter Menziuso Named EVP and President, BD Interventional
Latest SENS
- Senseonics Holdings Inc. filed SEC Form 8-K: Other Events
- Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems
- SEC Form SD filed by Senseonics Holdings Inc.
- Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026
- Chief Medical Officer Kaufman Francine was granted 63,177 shares, increasing direct ownership by 54% to 181,067 units (SEC Form 4)
- GC & Corp. Development Advisor Horton Kenneth L was granted 157,943 shares, increasing direct ownership by 115% to 295,057 units (SEC Form 4)
- Chief Operating Officer Jain Mukul was granted 270,759 shares, increasing direct ownership by 110% to 517,057 units (SEC Form 4)
- Director Fiorentino Edward was granted 9,852 shares, increasing direct ownership by 13% to 83,339 units (SEC Form 4)
- Director Defalco Stephen P was granted 9,852 shares, increasing direct ownership by 10% to 111,019 units (SEC Form 4)
- Director Roeder Douglas A was granted 9,852 shares, increasing direct ownership by 7% to 154,487 units (SEC Form 4)